Drug Type Probody drug conjugates |
Synonyms CAB-Axl antibody-drug conjugates, CAB-AXL-ADC, BA 3011 + [1] |
Target |
Mechanism AXL inhibitors(AXL receptor tyrosine kinase inhibitors), Tubulin inhibitors |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Inactive Organization |
Drug Highest PhasePhase 2 |
First Approval Date- |
RegulationOrphan Drug (US) |
Molecular FormulaC39H67N5O7 |
InChIKeyDASWEROEPLKSEI-UIJRFTGLSA-N |
CAS Registry474645-27-7 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Ovarian Cancer | Phase 2 | US | 12 Oct 2021 | |
Platinum-Resistant Ovarian Carcinoma | Phase 2 | US | 12 Oct 2021 | |
Platinum-Resistant Ovarian Carcinoma | Phase 2 | CA | 12 Oct 2021 | |
metastatic non-small cell lung cancer | Phase 2 | US | 17 Mar 2021 | |
metastatic non-small cell lung cancer | Phase 2 | GR | 17 Mar 2021 | |
metastatic non-small cell lung cancer | Phase 2 | HK | 17 Mar 2021 | |
metastatic non-small cell lung cancer | Phase 2 | IT | 17 Mar 2021 | |
metastatic non-small cell lung cancer | Phase 2 | PL | 17 Mar 2021 | |
metastatic non-small cell lung cancer | Phase 2 | ES | 17 Mar 2021 | |
metastatic non-small cell lung cancer | Phase 2 | TW | 17 Mar 2021 |
Phase 2 | 113 | vrahpzxbts(iwdnhajgeu) = The most common TEAEs of special interest among monotherapy pts were peripheral neuropathy (32.2%), neutropenia (25.3%), and abnormal liver function tests (20.7%). cpszpwekzl (lmhzphlcrv ) View more | Positive | 14 Mar 2024 | |||
BA3011 monotherapy and BA3011 + nivolumab | |||||||
GlobeNewswire Manual | Phase 2 | 40 | BA3011 | wbvmggudoc(kyeiheeuof) = lyllwklxnr hqfvgpwgei (nvgjxiuebc ) View more | Positive | 05 Dec 2023 | |
NCT03425279 (PRNewswire) Manual | Phase 2 | 17 | (先前 PD-1/L1、EGFR 或 ALK 抑制剂治疗失败的 AXL 阳性 NSCLC 患者) | llofpfikwu(vcnygglmbj) = zjveaqeddl hvltksxfgf (wlookibhlt ) View more | Positive | 12 Sep 2022 | |
(多形性肉瘤) | cfmgczcbhv(sibfkxelwg) = iojtiskhtc pfubmehftr (ghqxvhgdgk ) View more |